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BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a rare but highly aggressive variant of endometrial cancer.
Pertuzumab is a new humanised monoclonal antibody (mAb) targeting the epidermal growth factor type II receptor (HER2/neu).
We evaluated pertuzumab activity separately or in combination with trastuzumab against primary USPC cell lines expressing different
levels of HER2/neu.
METHODS: Six USPC cell lines were assessed by immunohistochemistry (IHC), flow cytometry, and real-time PCR for HER2/neu
expression. c-erbB2 gene amplification was evaluated using fluorescent in situ hybridisation (FISH). Sensitivity to pertuzumab and
trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) was
evaluated in 5h chromium release assays. Pertuzumab cytostatic activity was evaluated using proliferation-based assays.
RESULTS: Three USPC cell lines stained heavily for HER2/neu by IHC and showed amplification of the c-erbB2 gene by FISH.
The remaining FISH-negative USPCs expressed HER2/neu at 0/1þ levels. In cytotoxicity experiments against USPC with a high
HER2/neu expression, pertuzumab and trastuzumab were similarly effective in inducing strong ADCC. The addition of complement-
containing plasma and interleukin-2 increased the cytotoxic effect induced by both mAbs. In low HER2/neu USPC expressors,
trastuzumab was more potent than pertuzumab in inducing ADCC. Importantly, in this setting, the combination of pertuzumab
with trastuzumab significantly increased the ADCC effect induced by trastuzumab alone (P¼0.02). Finally, pertuzumab induced
a significant inhibition in the proliferation of all USPC cell lines tested, regardless of their HER-2/neu expression.
CONCLUSION: Pertuzumab and trastuzumab induce equally strong ADCC and CDC in FISH-positive USPC cell lines. Pertuzumab
significantly increases tratuzumab-induced ADCC against USPC with a low HER2/neu expression and may represent a new
therapeutic agent in patients harbouring advanced/recurrent and/or refractory USPC.
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Endometrial cancer is the most common female genital tract
malignancy in the United States, with an incidence of 40100 new
cases and 7470 deaths annually (Jemal et al, 2008). Two subtypes of
endometrial carcinoma, namely, type I and type II tumours, have
been described, on the basis of both clinical and histopathological
variables. Type I endometrial cancers, which account for the
majority of cases, are usually well differentiated and endometrioid
in histology. These neoplasms are frequently diagnosed in younger
women, are associated with a history of hyper-oestrogenism as the
main risk factor, and typically have a favourable prognosis with
appropriate therapy. In contrast, type II endometrial cancers are
poorly differentiated tumours, often with serous papillary (USPC)
or clear cell histology (Sorosky, 2008).
Uterine serous papillary adenocarcinomas are highly aggressive
tumours with propensity for lymphovascular invasion and
intraperitoneal and extra-abdominal spread, even at presentation
(Creasman et al, 2001). Although they account for only a minority
of endometrial cancers (i.e., o10%), about 40% of all relapses
occur in this group of patients. Furthermore, USPC tumours that
overexpress the HER2/neu receptor have a worse prognosis than
those that do not. Our group, as well as others, including large
cooperative studies reported by the Gynecologic Oncology Group,
has previously shown that up to 50% of USPC patients may
overexpress HER2/neu in their tumour, and these tumours may be
more biologically aggressive than cancers that do not overexpress
the receptor (Santin et al, 2002; Slomovitz et al, 2004; Santin et al,
2005a,b; Diaz-Montes et al, 2006; Villella et al, 2006; Grushko et al,
2008).
The erbB2 gene encodes for HER2/neu, a member of the erbB
receptor tyrosine kinase family. This is a family of four
transmembrane glycoproteins (erbB1, erbB2, erbB3, and erbB4)
that are expressed on epithelial, mesenchymal, and neuronal
cells (Yarden and Sliwkowski, 2001). Ligand binding results
in dimerisation of the receptor either with a twin receptor
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s(homodimerisation) or with one of its siblings (heterodimerisa-
tion) (Yarden and Sliwkowski, 2001). This leads to phosphoryla-
tion of intracellular tyrosine kinase residues that serve as docking
sites for various effectors and transcription factors that ultimately
modulate various biological responses, such as proliferation,
survival, migration, and differentiation. It is noteworthy that the
HER2/neu heterodimer is characterised by a stronger and more
diverse signalling potential than other erbB dimers (Yarden and
Sliwkowski, 2001). Importantly, HER2/neu overexpression has
been previously reported to be associated with cancer cell
proliferation, poor survival, and resistance to therapy in multiple
human tumours (Slamon et al, 1987; Berchuck et al, 1990, 1991;
Hetzel et al, 1992; Santin et al, 2005).
Pertuzumab (Omnitarg, Genentech, South San Francisco, CA,
USA), the first of a new class of agents designated as HER
dimerisation inhibitors, is a humanised IgG1 monoclonal antibody
(mAb) that sterically binds domain II of the erbB2 receptor. Unlike
trastuzumab (Herceptin), the principal mechanism of action of
which is believed to be through recruiting host immune cells
(natural killer (NK) cells) and setting off an antibody-dependent
cell-mediated cytotoxicity (ADCC) process (Clynes et al, 2000;
Gennari et al, 2004; Arnould et al, 2006), pertuzumab is believed to
inhibit a wider array of downstream signal transduction pathways
through inhibition of lateral signal transduction, that is, hetero-
dimerisation. Several in vitro and in vivo studies conducted on a
variety of human tumour cell lines have clearly elucidated this
mechanism of action (Mullen et al, 2007; Agus et al, 2002; Jackson
et al, 2004; Nahta et al, 2004; Takai et al, 2005). To our knowledge,
however, a therapeutic potential for pertuzumab has, thus far, not
been reported in endometrial cancer management.
In this study, to evaluate the potential clinical activity of
pertuzumab when used alone or in combination with trastuzumab,
we tested six USPC primary cell lines for HER2/neu receptor
expression and c-erbB2 gene amplification, and evaluated the
sensitivity of these biologically aggressive tumours expressing
different levels of HER2/neu to pertuzumab- and trastuzumab-
mediated ADCC and complement-dependent cytotoxicity (CDC) in
standard 5h chromium release assays. The potential in vitro
growth inhibition of pertuzumab, trastuzumab, and a combination
of the two mAbs in USPC cell lines was also studied.
METHODS
Establishment of USPC cell lines
Primary USPC tumour cell lines from six patients with invasive
USPC were obtained from fresh tumour biopsy samples collected
at the time of surgery, under approval of the Institutional Review
Board. Tumour samples were collected from patients who
experienced rapid tumour progression during adjuvant chemo-
therapy after primary surgical debulking. Tumours were staged
according to the International Federation of Gynecologists and
Obstetricians operative staging system. Patient characteristics are
described in Table 1. Six primary USPC cell lines (USPC ARK-1,
USPC ARK-2, USPC ARK-3, USPC ARK-4, USPC ARK-5, and
USPC ARK-6) were established after sterile processing of tumour
samples from surgical biopsy specimens, as described previously
for ovarian carcinoma specimens (Santin et al, 1996). Primary
USPC cell lines with limited passages (i.e., o50) were analysed by
flow cytometry for HER2/neu expression immediately after tumour
processing and after in vitro culture from 1 week to 3 years.
Immunostaining of formalin-fixed tumour tissues and
cell blocks obtained from primary USPC
Formalin-fixed, paraffin-embedded tissue blocks from the six
USPC patients from whom primary cell lines were established were
retrieved from surgical pathology files. Specimens were reviewed
by a surgical pathologist. The level of expression of HER2/neu was
then evaluated on the most representative block by standard
immunohistochemical staining, using the Hercept test (Dako,
Glostrup, Denmark). Briefly, immunohistochemical stainings were
performed on 4-mm sections of formalin-fixed, paraffin-embedded
tissue. After pretreatment with 10mM citrate buffer at pH 6.0 using
a steamer, they were incubated with anti-HER-2/neu polyclonal Ab
(Dako) at a 1:200 dilution. Slides were subsequently labelled with
streptavidin-biotin (LSAB; Dako), stained with diaminobenzidine,
and counterstained with haematoxylin.
Similarly, cell cultures from all six primary cell lines used in
cytotoxicity experiments were trypsinised, and cells were sus-
pended in a cytorich fixative (Richard Allen Scientific, Kalamazoo,
MI, USA) and centrifuged for 5min at 2650r.p.m. The supernatant
was removed without disturbing the cell button. Four drops of
human plasma and four drops of thromboplastin (Simplastin
Excel, Biomerieux, Durham, NC, USA) were added to resuspend
the cell button. Specimens were set aside until a clot formed
(generally 5min). The clot was then placed in a mesh bag, fixed in
10% buffered formalin, and processed as per the routine
histological technique. HER2/neu immunohistochemical stainings
were performed on paraffin-embedded 5mm sections of cell blocks
after deparaffinisation and rehydration, using the HercepTest kit
(Dako) according to the manufacturer’s instructions. HER2/neu
intensity of staining was graded as 0 (negative¼no staining,
or membrane staining in o10% of tumour cells), 1þ (light
staining¼a faint/barely perceptible partial membrane staining
in 410% of tumour cells), 2þ (moderate staining¼a weak-to-
moderate membrane staining in 410% of tumour cells), or 3þ
(heavy staining¼a strong complete membrane staining in 410%
of tumour cells). Appropriate positive and negative controls were
used with each case.
FISH of cell blocks obtained from primary USPC
Fluorescent in situ hybridisation (FISH) analysis was performed
using the PathVysion Her-2 DNA FISH Kit (Abbott Molecular Inc.,
Abbott Park, IL, USA) according to the manufacturer’s instructions.
Briefly, 5mm sections of cell blocks were deparaffinised and
rehydrated, followed by acid pretreatment and proteinase K
digestion. A probe mix containing an orange probe directed
against the Her2 gene (Vysis, Inc., Downers Grove, IL, USA, LSI
Her2/neu) and a green probe directed against the pericentromeric
region of chromosome 17 (Vysis CEP 17) were added and specimens
were denatured for 5min at 731C. The slides were then incubated
overnight in a humidity chamber at 371C. On the following day, the
slides were washed and a fluorescence mounting medium contain-
ing 4,6-diamidino-2-phenylindole (DAPI) was applied. Fluorescent
signals in at least 30 non-overlapping interphase nuclei with intact
morphology were scored using a Zeiss Axioplan 2 microscope (Carl
Zeiss Meditec, Inc., Dublin, CA, USA) with a  100 planar objective,
using a triple band-pass filter that permits simultaneous blue, green,
and red colours. Tumour cells were scored for the number of red
(HER2/neu) and green (chromosome 17) signals. A case was scored
as amplified when the ratio of the number of fluorescent signals
of HER2/neu to chromosome 17 (R/G) was X2. The ploidy status of
chromosome 17 was determined by calculating the average number
of copies of chromosome 17 on the basis of the count of 30 cell
nuclei. Disomy was defined as a chromosome 17 number of 1.5–2.5.
Such a range took into account that even a given tumour specimen
with predominantly disomy 17 could still show some deviation from
an average of two signals per cell, because of the genetic instability of
the tumour, high mitotic index, and potential nuclear truncation
through tissue sectioning. Chromosome 17 polysomy was defined as
a chromosome 17 average number of 42.5. Monosomy was defined
as a chromosome 17 average number of o1.5.
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The clinically marketed anti-HER/neu mAb pertuzumab (Omni-
targ; Genentech Inc) was used for our study. For comparison,
we also used the anti HER/neu trastuzumab (Herceptin; Genen-
tech). Both pertuzumab and trastuzumab are humanised mAbs of
the G1 type that bind, with high affinity, the extracellular domain
of the HER/neu receptor (Mr 185000 transmembrane glycopro-
tein). Whereas pertuzumab binds domain II, trastuzumab binds
domain IV. For staining, a fluorescein isothiocyanate-conjugated
goat antihuman F(ab1)2 immunoglobulin was used as a secondary
reagent (BioSource International, Camarillo, CA, USA). Analysis
was conducted with a FACScalibur, using cell Quest software
(BD Biosciences, San Diego, CA, USA).
Quantitative real-time–PCR
RNA isolation from all six primary USPC cell lines used in
cytotoxicity experiments was performed using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s
instructions. Quantitative PCR was carried out with a 7500 Real-
Time PCR System using the manufacturer’s recommended
protocol (Applied Biosystems, Foster City, CA, USA) to evaluate
the expression of erbB2 in all samples. Each reaction was run in
duplicate. Briefly, 5mg of total RNA from each sample was reverse
transcribed using SuperScript III first-strand cDNA synthesis
(Invitrogen). Five microlitres of reverse-transcribed RNA samples
(from 500ml of total volume) were amplified using the TaqMan
Universal PCR Master Mix (Applied Biosystems) to produce PCR
products specific for erbB2. The primers and probe for erbB2 were
obtained from Applied Biosystems (Assay ID Hs00170433_m1).
The comparative threshold cycle (CT) method (Applied Biosys-
tems) was used to determine gene expression in each sample,
relative to the value observed in the lowest non-malignant
endometrial epithelial cell sample, using glyceraldehyde-3-phos-
phate dehydrogenase (Assay ID Hs99999905_m1) RNA as internal
control.
Tests for ADCC
A standard 5h chromium (
51Cr) release assay was performed to
measure the cytotoxic reactivity of Ficoll-Hypaque-separated
peripheral blood lymphocytes (PBLs) from several healthy donors
in combination with trastuzumab and/or pertuzumab against
USPC target cell lines. The release of
51Cr from target cells was
measured as described (Santin et al, 1999), as evidence of tumour
cell lysis after exposure of tumour cells to various concentrations
of trastuzumab and pertuzumab (ranging from 1 to 100mgml
 1)
and different target/effector cell ratios. Controls included the
incubation of target cells alone or with PBLs or mAb separately.
The chimeric anti-CD20 mAb rituximab (Rituxan; Genentech) was
used as control in all bioassays. Antibody-dependent cell-mediated
cytotoxicity was calculated as the percentage of killing of target
cells observed with mAb plus effector cells as compared with
51Cr
release from target cells incubated alone.
Test for complement-mediated target cell lysis and
c-globulin inhibition
A standard 5h chromium (
51Cr) release assay identical to that used
for ADCC assays, except that human plasma (as a source of
complement) diluted 1:2 was added in place of effector cells, was
used to test for complement-mediated target cell lysis. To test for
the possible inhibition of ADCC against USPC cell lines by
physiological human plasma concentrations of g-globulin, heat-
inactivated (561C for 30min) human plasma was diluted 1:2
before being added in the presence or absence of effector PBLs. In
some experiments, non-heat-inactivated human plasma (diluted
1:2) was added in the presence of effector PBLs. Controls included
the incubation of target cells alone or with either lymphocytes or
mAb separately. Rituximab was used as control mAb.
IL-2 enhancement of ADCC
To investigate the effect of interleukin-2 (IL-2) on pertuzumab-
mediated ADCC, effector PBLs were incubated for 5h at 371Ca ta
final concentration of IL-2 (Aldesleukin; Chiron Therapeutics,
Emeryville, CA, USA) ranging from 50 to 100IUml
 1 in 96-well
microtitre plates. Target cells were primary USPC cell lines
exposed to pertuzumab (concentrations ranging from 1 to
100mgml
 1), whereas controls included the incubation of target
cells alone or with PBLs in the presence or absence of IL-2 or mAb,
respectively. Rituximab was used as control mAb. ADCC was
calculated as the percentage of killing of target cells observed with
mAb plus effector PBLs, as compared with target cells incubated
alone.
Proliferation assay
To evaluate the potential cytostatic effect of pertuzumab on
primary USPC cell lines, cells were seeded in a 96-well plate at a
density of 2000–5000 cells per well in RPMI 1640 medium
(Invitrogen) with 10% foetal bovine serum (Gemini, Woodland,
CA, USA). After 24h, pertuzumab, trastuzumab, and a 1:1
combination of both antibodies were added at a final concentra-
tion of 20mgml
 1. The final volume of medium per well was set at
100ml. After 48–72h, proliferation was evaluated using CellTiter
96 Aqueous One Solution cell proliferation assay (Promega,
Madison, WI, USA), as directed by the manufacturer. Results of
this colorimetric assay were interpreted as percentage inhibition of
proliferation compared with control cells growing in culture
medium devoid of antibodies or in the presence of rituximab.
Statistical analysis
For quantitative real-time PCR (qRT–PCR) data, right skewing
was removed by considering copy-number ratios relative to the
lowest-expressing NEC sample (‘relative copy numbers’), log2-
transforming them to DCTs, and comparing the results using an
unequal-variance t-test for the USPC-vs-NEC difference. Group
means with 95% confidence intervals (CIs) were calculated by
Table 1 Patient characteristics from which the six USPC cell lines were established
Patient Age (years) Race Year of diagnosis FIGO
a stage USPC histopathology
USPC ARK-1 62 AA 1997 IVA Pure
USPC ARK-2 63 AA 1998 IVB Pure
USPC ARK-3 59 AA 2006 IVB Mixed
USPC ARK-4 73 C 2004 IVB Pure
USPC ARK-5 73 AA 2006 IIIC Pure
USPC ARK-6 62 C 2005 IB Mixed
Abbreviations: AA¼African American; C¼Caucasian; USPC¼uterine serous papillary adenocarcinoma.
aFIGO, International Federation of Gynecology and Obstetrics.
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to obtain means (95% CIs) of relative copy numbers. Differences
in the HER2/neu expression by flow cytometry were analysed by
an unpaired t-test, and a P-value o0.05 among samples
was considered to be significant. The Wilcoxon rank–sum test
was used to compare USPC types to normal endometrium for
differences in immunohistochemistry (IHC) staining intensities.
Sample-type differences were expressed as odds ratios accompa-
nied by 95% CIs. The Kruskal–Wallis test and w
2 analysis were
used to evaluate the differences in HER2/neu-induced ADCC levels
and inhibition of proliferation in primary tumour cell lines.
Statistical analysis was performed using SPSS version 15 (SPSS,
Chicago, IL). A P-value of o0.05 was considered as being
statistically significant.
RESULTS
HER2/neu expression by IHC in USPC tissue blocks
and primary USPC cell lines
Using formalin-fixed paraffin blocks of USPC tissues from which
the six primary tumour cell lines were established, HER2/neu
expression was detected by IHC (i.e., score from 1þ to 3þ) in all
six samples. Three samples showed a moderate-to-strong mem-
brane staining (i.e., 2þ,3 þ), whereas the remaining three
showed weak staining (1þ) (Figure 1A and Table 2). To determine
whether the high, moderate, or low expression of the HER2/neu
receptor detected on USPC tissue blocks may differ in the primary
USPC cell lines because of the potential selection of a sub-
population of cancer cells present in the original tumour, or
whether in vitro expansion conditions may have modified receptor
expression, we performed additional immunohistochemical
analysis of HER2/neu on the cell blocks obtained from all six
primary USPC culture cell lines used in cytotoxicity experiments.
Strong membrane staining for HER2/neu (3þ) in cell blocks was
confirmed by IHC in USPC ARK-1 and USPC ARK-2 cell lines.
USPC ARK-3 was found to express HER2/neu at the 3þ level on
the cell block of cultured tumour cells, whereas on the original
tissue block, HER2/neu was reported at the 2þ level (Table 2,
Figure 1A). USPC ARK-6 showed weak membrane staining (1þ)
in the cell block and in the original tissue block. One score
difference in staining intensity was noted between paraffin-
embedded tumour tissues and cell blocks obtained from the
remaining two cell lines (i.e., USPC ARK-4 and USPC ARK-5)
(Table 2). This minor discrepancy in scoring USPC with low
HER2/neu expression is likely to be related to test reproducibility
and/or inter-observer variability.
HER2/neu expression by qRT–PCR in USPC
Uterine serous papillary adenocarcinoma cell lines grown as
primary cultures were tested by qRT–PCR to confirm at mRNA
level the different HER2/neu surface receptor expressions. Normal
endometrial samples were used as negative controls. mRNA
copy number for USPC ARK-1, USPC ARK-2, and USPC ARK-3
(i.e., high HER2/neu expressors by IHC) were 373, 607, and 677,
respectively. This was compared with an mRNA copy number of
7, 13, and 6 in USPC ARK-4, USPC ARK-5, and USPC ARK-6 (i.e.,
low HER2/neu expressors by IHC), respectively (Table 2). These
data are in full agreement with the results obtained by IHC and
flow cytometry.
erbB2 gene amplification by FISH and ploidy in USPC
Fluorescent in situ hybridisation was performed on formalin-fixed
paraffin-embedded tissue blocks from four USPCs, as well as
on the cell blocks obtained from all six primary cell lines used
in cytotoxicity experiments. Test results are shown in Table 2.
erbB2 gene amplification was detected in USPC ARK-1, USPC
ARK-2, and USPC ARK-3, suggesting that the strong receptor
expression and high HER2/neu mRNA level are likely caused by
gene amplification. In contrast, USPC ARK-4, USPC ARK-5, and
USPC ARK-6 were found to be negative for erbB2 gene
amplification (Table 2). When the chromosome 17 average copy
number was calculated, polysomy was identified in four primary
cell lines (i.e., USPC ARK-1, USPC ARK-4, USPC ARK-5, and
USPC ARK-6), whereas disomy was evident in the two remaining
cell lines (i.e., USPC-ARK-2 and USPC-ARK-3).
HER2/neu expression by flow cytometry in primary USPC
The HER2/neu receptor expression was evaluated by FACS analysis
on all six primary USPC cell lines using trastusumab, pertuzumab,
and a combination of the two mAbs. In addition, as negative
controls, several B-cell lines (EBV-transformed lymphoblastoid B
cell lines) established from the same USPC patients from whom
the tumour cell lines had been established were also studied. Very
high reactivity against HER2/neu was found in 100% of primary
USPC ARK-1, USPC ARK-2, and USPC ARK-3 cell lines using
either pertuzumab or trastuzumab (mean fluorescence intensity
(MFI) ranging from 387 to 1381) (Figure 1B, Table 3). Significantly
lower HER2/neu expression was observed in USPC ARK-4, USPC
ARK-5, and USPC ARK-6 (i.e., MFI range 13 to 31) (Figure 1B,
Table 3). These findings obtained with viable (i.e., not fixed)
tumour cells are consistent with the IHC results obtained on the
tissue block and fixed cell lines and confirm a higher expression
of HER2/neu in our first three cell lines compared with the latter
ones. HER2/neu expression in all USPC samples was higher than
that in negative controls (data not shown). Importantly, in
matched experiments, we found the combination of pertuzumab
and trastuzumab to consistently provide a significantly higher MFI
for HER2/neu in six out of six (100%) USPC cell lines when
compared with the HER2/neu MFI results obtained using either
antibody alone (Table 3). These results are likely to be related to
the fact that trastuzumab and pertuzumab recognise two different
epitopes on the surface of USPC cell lines.
USPCs are resistant to NK activity but sensitive to
pertuzumab-mediated ADCC
All six primary USPC cell lines available were tested for their
sensitivity to NK cytotoxicity when challenged with heterologous
PBLs collected from several healthy donors in a standard 5h
51Cr release assay (Table 4). USPC cells were consistently found to
be resistant to NK-mediated cytotoxicity when combined with
PBLs at E:T ratios varying from 25:1 to 50:1 (range of cyto-
toxicity from 0.8 to 10% with all E:T ratios). Similarly, USPC cell
lines incubated with the rituximab (2.5mgml
 1) control antibody
endured no significant cytotoxicity (range from 0.3 to 8.6%).
We then investigated the sensitivity of USPC cell lines to
heterologous PBLs in the presence of pertuzumab (2.5mgml
 1),
trastuzumab (2.5mgml
 1), and a combination of both (Table 4). In
cell lines expressing high levels of erbB2 (i.e., USPC ARK-1, USPC
ARK-2, and USPC ARK-3), high cytotoxicity was achieved with
pertuzumab (mean±s.d., 61±25.6%; range, 32.5–67.3%;
P¼0.0001) and trastuzumab (mean±s.d., 56.3±14.2%; range,
32.5–77.1%; P¼0.0001) compared with control, that is, either
PBLs alone (mean±s.d., 3.2±5.6%; range, 0–19%) or PBLs and
rituximab (mean±s.d., 2.5±3.8%; range, 0–13%), in multiple
experiments. No significant difference in cytotoxicity was found
between the two antibodies in high HER2/neu expressors (Table 4).
The upper panel of Figure 1C depicts the mean cytotoxicity
induced by pertuzumab, trastuzumab, and the combination of
both mAbs in high-expressor USPC cell lines.
In cell lines expressing low levels of erbB2 (i.e., USPC ARK-4,
USPC ARK-5, and USPC ARK-6), significant cytotoxicity was
Pertuzumab in USPC
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Figure 1 (A) Upper panel: Representative HER2/neu expression by immunohistochemistry (IHC) in uterine serous papillary adenocarcinoma (USPC) cell
blocks. Left: USPC ARK-4 shows negative staining for HER2/neu; Right: USPC ARK-3 shows strong (3þ) staining for HER2/neu. Middle panel:
Representative HER2/neu expression by IHC in USPC tissue blocks. Left: USPC ARK-6 shows low/negative staining for HER2/neu; Right: USPC ARK-2
shows strong (3þ) staining for HER2/neu. Lower panel: Representative example of negative (USPC ARK-6, left) vs positive (USPC-ARK2, right) fluorescent
in situ hybridisation (FISH) amplification of the c-erbb2 gene. Tumour cells were scored for the number of red (HER2/neu) and green (chromosome 17)
signals as described in the Methods section. (B) Flow cytometry histograms of primary USPC cell lines showing high (USPC ARK-1, USPC ARK-2, and USPC
ARK-3) and low (USPC ARK-4, USPC ARK-5, and USPC ARK-6) expression of HER2/neu. Rituximab-anti-CD20 control antibody (solid line); trastuzumab
(dashed line); pertuzumab (dotted line). (C) Left panel: Antibody-dependent cytotoxicity (mean±s.d.) in USPC cell lines with high HER2/neu expression
(i.e., USPC ARK-1, -2, and -3). Average percentage cytotoxicity in high expressors from six independent matched experiments, showing significantly higher
cytotoxicity with trastuzumab (the Kruskall–Wallis test and w
2 analysis, P¼0.001), pertuzumab (P¼0.0001), and combination of pertuzumab and
trastuzumab (P¼0.001) when compared with either peripheral blood lymphocytes (PBLs) only or control antibody rituximab. E:T, effector to target cell
ratio. Right panel: Antibody-dependent cytotoxicity (mean±s.d.) in USPC cell lines with a low HER2/neu expression (i.e., USPC ARK-4, -5, and -6).
Average percentage cytotoxicity in low expressors from 12 independent experiments, showing significantly higher cytotoxicity with trastuzumab (Po0.01),
pertuzumab (P¼0.01), and combination of pertuzumab and trastuzumab (P¼0.01) when compared with either PBLs only or control antibody rituximab.
Combination of pertuzumab and trastuzumab (total dose 2.5mgml
 1) induced significantly higher cytotoxicity (P¼0.001) when compared with either
trastuzumab (2.5mgml
 1) or pertuzumab (2.5mgml
 1) alone. E:T, effector to target cell ratio.
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0.4–32%) compared with either PBLs alone (mean±s.d., 4±4%;
range, 0–13%; P¼0.001) or PBLs and rituximab (mean±s.d.,
2.4±1.8%; range, 0.2–4.8%; P¼0.001). Similarly, significant
cytotoxicity was also achieved with trastuzumab (mean±s.d.,
21±18%; range, 3–56%) compared with either PBLs alone
(mean±s.d., 4±4%; range, 0–13%; P¼0.015) or PBLs and
rituximab (mean±s.d., 2.4±1.8%; range, 10.2–4.8%; P¼0.018).
Trastuzumab induced significantly higher cytotoxicity than
pertuzumab in matched experiments (P¼0.01). Both pertuzumab
and trastuzumab produced significantly higher cytotoxicity
(mean±s.d., 32±18%; range, 9–66%) when compared with
PBLs (P¼0.001) or PBLs and rituximab (P¼0.001) (Table 4).
Importantly, when pertuzumab and trastuzumab were used in
combination against USPC with a low HER2/neu expression,
the cytotoxicity achieved was significantly higher than that
achieved by either pertuzumab (P¼0.001) or trastuzumab
(P¼0.01) used alone (Table 4, Figure 1C, lower panel). This
implies that the combination of trastuzumab and pertuzumab may
potentiate the induction of ADCC against USPC that expresses low
levels of HER2/neu.
Effect of complement and endogenous IgG on
pertuzumab-mediated ADCC against USPC
To evaluate primary USPC cell lines for their sensitivity to
complement-mediated cytotoxicity and to evaluate possible
inhibition of ADCC by endogenous IgG, five USPC cell lines (i.e.,
three high HER2/neu expressors, namely, USPC ARK-1, USPC
ARK-2, and USPC ARK-3; and two low HER2/neu expressors,
namely, USPC ARK-5 and USPC ARK-6) were challenged with
human plasma diluted 1:2 (with and without heat inactivation) in
the presence and absence of effector cells and pertuzumab in
standard 5h
51Cr release assay. The addition of untreated plasma
in the absence of PBL with or without pertuzumab was unable to
induce significant cytotoxicity against any of the USPC cell lines
(data not shown). These data illustrate the lack of significant
cytotoxicity mediated by complement proteins in the absence
of effector cells. Furthermore, the addition of endogenous IgG
(i.e., heat-inactivated plasma, diluted 1:2) to PBLs in the presence
of pertuzumab did not significantly alter the degree of ADCC.
In contrast, as shown in Figure 2A, the addition of untreated
plasma (diluted 1:2) to PBLs in the presence of pertuzumab
consistently increased ADCC against all USPC primary cell lines
regardless of their expression of HER2/neu (i.e., pertuzumab
þplasma: mean±s.d., 50±17%; range, 14–71% vs pertuzumab
alone: mean±s.d., 40±21%; range, 13–71%; P¼0.01). Similarly,
pertuzumab in combination with plasma induced significantly
higher cytotoxicity when compared with PBLs treated with plasma
(P¼0.001) or PBLs treated with plasma in the presence of
rituximab (P¼0.001). Taken together, these results show that
pertuzumab induces CDC in USPC cell lines.
IL-2 enhancement of ADCC against USPC
To investigate the effect of low doses of IL-2 in combination with
pertuzumab (2.5mgml
 1) on ADCC against USPC cell lines, PBLs
from healthy donors were incubated for 5h in the presence of
50–100IUml
 1 of IL-2. As representatively shown in Figure 2B for
all USPC cell lines tested (i.e., two high HER2/neu expressors,
namely, USPC ARK-2 and USPC ARK-3; and two low HER2/neu
expressors, namely, USPC ARK-5 and USPC ARK-6), significantly
Table 4 Antibody-dependent cellular cytotoxicity results in six USPC cell lines
Sample Control (%) Rituximab (%) Trastuzumab (%)
a Pertuzumab (%)
a Combination (%)
b
USPC ARK-1 1.6 4.5 44.7 52.8 54.2
USPC ARK-2 0.7 0.5 63.8 62 58.1
USPC ARK-3 0.6 1.9 67.3 66.7 68.8
USPC ARK-4 0.2 0.4 14.1 2.2 26.1
USPC ARK-5 4.7 3.7 34.5 17.7 41.1
USPC ARK-6 4.6 4.5 56.2 25.3 65.7
Abbreviation: USPC¼uterine serous papillary adenocarcinoma.
aDose of pertuzumab and trastuzumab was 2.5mgml
 1.
bPertuzumab 1.25mgml
 1 and trastuzumab
1.25mgml
 1. The combination of pertuzumab and trastuzumab was significantly more effective in inducing antibody-dependent cell-mediated cytotoxicity in all three USPC cell
lines that express low levels of HER2/neu when compared with the use of pertuzumab or trastuzumab used alone (Kruskal–Wallis test and w
2 analysis; P¼0.001). Results from
a representative cytotoxicity experiment for each cell lines are shown.
Table 3 HER2/neu expression in primary USPC cell lines by flow
cytometry
Pertuzumab
a Trastuzumab
a Combination
a
Sample (%) MFI (%) MFI (%) MFI P-value
b
USPC ARK-1 100 407.5 100 387.4 100 602.7 0.03
USPC ARK-2 100 1366 100 1381 100 1742 0.03
USPC ARK-3 100 607.5 100 679.7 100 751.8 0.04
USPC ARK-4 100 13.2 100 14.8 100 20.6 0.02
USPC ARK-5 100 31.7 100 30.7 100 45.5 0.04
USPC ARK-6 100 30.3 100 31.0 100 50.1 0.03
Abbreviations: MFI¼mean fluorescence intensity; USPC¼uterine serous papillary
adenocarcinoma.
aDose of pertuzumab and trastuzumab was 2.5mgml
 1. Total dose
of the combination was 2.5mgml
 1.
bUnpaired samples t-test. Results of a matched
flow cytometry experiment are shown and are representative of a minimum of three
experiments for each USPC primary cell line. From each primary tumour sample
5000–10000 gated cells were measured and analysed using a FACScalibur, using cell
Quest software, as described in the Methods section.
Table 2 HER2/neu expression in primary USPC cell lines
IHC FISH RT–PCR
Sample Tissue
Cell
Block Tissue
Cell
Block
mRNA copy
number
Control 1
USPC ARK-1 3+ 3+ 3.1 2.5 373
USPC ARK-2 3+ 3+ 6.3 5.2 607
USPC ARK-3 2+ 3+ N/A 4.7 677
USPC ARK-4 1+ 0 1.7 1.6 7
USPC ARK-5 1+ 0 1.5 1.4 13
USPC ARK-6 1+ 1+ N/A 0.9 6
Abbreviations: FISH¼fluorescent in situ hybridisation; IHC¼immunohistochemistry;
RT–PCR¼real-time PCR; N/A¼not available for testing; USPC¼uterine serous
papillary adenocarcinoma. Tissue refers to formalin-fixed, paraffin-embedded tissue
blocks of the original tumour sample. Cell Block refers to formalin-fixed, paraffin-
embedded cell blocks obtained from primary cell lines in culture.
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shigher cytotoxicity was evident when pertuzumab was combined
with IL-2 (mean±s.d., 46.9±11.%; range, 22.4–74.2%) vs the
use of pertuzumab alone (mean±s.d., 41.5±12.8%; range,
15.8–71.9%; P¼0.04). Similarly, pertuzumab in combination with
IL-2 induced significantly higher cytotoxicity when compared
with PBLs treated with IL-2 (P¼0.03) or PBLs treated with
IL-2 in the presence of rituximab (P¼0.03). In contrast, no
significant increase in cytotoxicity was detected after 5h of IL-2
treatment in the absence of pertuzumab or in the presence of
rituximab control mAb (Figure 2B). These results suggest that
low levels of IL-2 may enhance ADCC mediated by pertuzumab
in vitro in both high and low HER2/neu expression USPC cell lines.
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Figure 2 (A) Representative effect of human plasma (diluted 1:50) on cytotoxicity induced by PBLs in a total of 13 independent experiments in five
uterine serous papillary adenocarcinoma (USPC) cell lines including three high HER2/neu expressors and two low expressors. Addition of plasma (diluted
1:2) to PBL in the presence of pertuzumab caused a significant increase in cell lysis (mean±s.d., P¼0.01), attributable to complement-mediated
cytotoxicity. Inactivation of complement by heating annihilated this effect. PBL, peripheral blood lymphocytes; mAb, monoclonal antibody; PL, plasma; HI PL,
heat-inactivated plasma. (B) Representative examples of interleukin-2 (IL-2) enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC)
mediated by pertuzumab (2.5mgml
 1) against two high (i.e., USPC-ARK-2 and -3) and two low (i.e., USPC-ARK-5 and -6) HER2/neu expressor USPC cell
lines.
51Cr-labelled USPC cells (10000 cells per sample) were incubated in the presence of 100IUml
 1 of IL-2 for 5h. Effector PBL with medium only or in
the presence of rituxan (2.5mgml
 1) was used as control. Pertuzumab-mediated ADCC was significantly enhanced in both high and low HER2/neu
expressor USPC cell lines when compared with controls (P¼0.04). Similar results were obtained after incubation of effector PBL with 50IUml
 1 of IL-2
(data not shown). (C) Representative effect of pertuzumab, trastuzumab, and a combination of the two mAbs on the proliferation of USPC cell lines with a
high (upper panel) and low (lower panel) Her2/neu expression. Tumour cells were seeded in 96-well plates (2500–3000 cells per well) in the presence of
pertuzumab (20mgml
 1), trastuzumab (20mgml
 1), or a combination of both antibodies (total concentration 20mgml
 1, ratio 1:1) as described in the
Methods section. After 72h, proliferation was measured using CELLTITER 96 AQueous One Solution Cell Proliferation Assay (Promega). Data are
presented as mean±s.d. of a total of 33 independent experiments. Both pertuzumab and trastuzumab induced a significant reduction in the proliferation of
cells when compared with control cells (the Kruskal–Wallis test and w
2 analysis, P¼0.0001). Pertuzumab alone and the combination of pertuzumab and
trastuzumab were significantly more effective than trastuzumab alone (P¼0.03).
Pertuzumab in USPC
K El-Sahwi et al
140
British Journal of Cancer (2010) 102(1), 134–143 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sPertuzumab inhibits in vitro proliferation of USPC
cell lines
Inhibition of proliferation by pertuzumab was tested in vitro in
all six primary USPC cell lines endowed with a high and low
HER2/neu expression. The effect of pertuzumab (20mgml
 1) was
compared with that of trastuzumab (20mgml
 1) and with a
combination of both antibodies (total concentration 20mgml
 1,
ratio 1:1). Cell proliferation was significantly inhibited in the
presence of pertuzumab, trastuzumab, and the combination of the
two mAbs in all USPC cell lines tested, with the percentage of
inhibition varying from 4 to 59% (pertuzumab), 3 to 48%
(trastuzumab), and 7 to 63% (mAbs combination) in multiple
experiments (Po0.001) (Figure 2C). Pertuzumab was significantly
more effective than trastuzumab in inhibiting the proliferation of
USPC cell lines regardless of their high or low HER2/neu
expression (Po0.001). The combination of pertuzumab and
trastuzumab was more cytostatic when compared with that of
trastuzumab used alone against all cell lines (Figure 2C, Po0.005).
Finally, a combination of pertuzumab and trastuzumab was
significantly more cytostatic against the high Her2/neu expressor
cell lines when compared with pertuzumab used alone (Figure 2C,
Po0.01).
DISCUSSION
Our group has recently reported HER2/neu overexpression by
IHC and amplification of the c-erbB2 gene by FISH in a large
percentage of patients harbouring USPC (Santin et al, 2002; Santin
et al, 2005a,b). These findings, which have been recently
confirmed by other groups (Diaz-Montes et al, 2006), as well as
those in cooperative multicentric studies reported by the
Gynecologic Oncology Group (Grushko et al, 2008), have high-
lighted the potential of targeting HER2/neu as a new therapeutic
marker in patients harbouring aggressive type II carcinomas such
as USPC. Similar to the great promise for treatment of metastatic
breast cancer in patients harbouring tumours with proven
amplification or strong (i.e., 3þ by IHC) HER2/neu overexpres-
sion, endometrial cancer patients with disease refractory to
standard treatment modalities may potentially benefit from
HER2/neu-targeted therapy. Consistent with this view, in this
study we demonstrated that HER2/neu is highly expressed in three
out of the six primary USPC cell lines established in our
laboratory. Overexpression of the HER2/neu receptor was demon-
strated by IHC and flow cytometry, and was also correlated with
both mRNA expression and gene amplification by qRT–PCR and
FISH, respectively.
In a previous study, we reported significant trastuzumab-
induced ADCC in USPC cell lines showing strong (i.e., 3þ) HER2/
neu overexpression (Santin et al, 2002). In this study, we carefully
analysed and compared the potential cytotoxic activity of
pertuzumab with that of trastuzumab in multiple USPC cell lines
expressing different levels of HER2/neu. In addition, we studied
and compared the effect of the combination of pertuzumab and
trastuzumab in eliciting ADCC against these tumours. Our results
showed for the first time high sensitivity to pertuzumab-induced
ADCC in all six primary USPC cell lines available in this study.
In this regard, when USPC showing erbB2 gene amplification by
FISH was challenged by PBLs and pertuzumab in a standard 5h
chromium (
51Cr) release assay, significant levels of cytotoxicity,
comparable with those achieved by trastuzumab, were consistently
observed.
Although in vivo and in vitro studies have proposed several
mechanisms of action for IgG1 mAbs, such as trastuzumab
and pertuzumab, including receptor downmodulation and down-
stream signal inhibition, ADCC has evolved as an instrumental
mechanism to explain the clinical activity of these mAb (Clynes
et al, 2000; Gennari et al, 2004; Arnould et al, 2006). Consistent
with this view, Gennari et al (2004) demonstrated a correlation
between tumour response to trastuzumab and in vitro ADCC in
erbB2
þ breast cancer patients receiving trastuzumab preopera-
tively. Similarly, Arnould et al (2006) showed that breast cancer
patients who responded well to neoadjuvant trastuzumab and
docetaxel had an increased tumour infiltration with lymphocytes,
NK cells, and cytotoxic proteins such as granzyme B than patients
who had a poor response.
The degree of ADCC, however, is variable even in HER2/neu
overexpressors, and is mainly dependent on the number and
function of NK cells (Varchetta et al, 2007). Natural killer cells are
considered to be the best-suited lymphocytes for ADCC because
they carry FcgRIII receptors, which are activator molecules, and
not FcgRIIb receptors, which inhibit ADCC (Carson et al, 2001).
Natural killer cells also carry receptors for IL-2, a cytokine that
induces expansion of the NK cell population and enhances their
function (Repka et al, 2003). Outpatient low-dose IL-2 has,
therefore, been previously used to enhance cancer patients’
immune response to mAbs with little toxicity (Carson et al,
2001; Repka et al, 2003). Consistent with this, a significant increase
in ADCC against USPC was detected after exposure of PBLs
from healthy donors to low doses of IL-2 in vitro for a brief time
(i.e., 5h). These data, therefore, suggest that the administration
of low, non-toxic doses of IL-2 in vivo may enhance the function
of effector cells and increase the efficacy of pertuzumab therapy in
USPC patients. Given the resistance of this tumour to standard
anti-cancer therapy, these combined therapies might be particu-
larly important in the treatment of USPC patients.
Both pertuzumab and trastuzumab induced significant ADCC
against cell lines that express low HER2/neu levels, when compared
with PBLs alone. However, the level of ADCC induced against these
tumours was significantly lower than that detectable against USPC
showing amplification of the erbB2 gene by FISH. Surprisingly,
in our experiments, when USPC cell lines that do not overexpress
HER2/neu were subjected to a combination of pertuzumab and
trastuzumab in a standard 5h
51Cr release assay, the drug
combination induced significantly higher cytotoxicity levels
compared with control and either antibody used alone. The reason
for this is not readily apparent, as both mAbs have a high affinity
to the erbB2 receptor (Adams et al, 2006). Notably, in previous
studies, pertuzumab was far more effective than trastuzumab in
inhibiting the proliferation of breast cancer cell lines expressing
varying levels of HER2/neu (Agus et al, 2002; Nahta et al, 2004).
This was attributed to pertuzumab’s ability to inhibit ligand-
dependent heterodimerisation and activation of downstream
targets such as mitogen-activated protein kinase and Akt. In
addition, pertuzumab was found to inhibit ligand-dependent
activation and signalling in several other cell lines (Jackson et al,
2004; Takai et al, 2005). Although a synergistic effect on signal
transduction inhibition in those cell lines is certainly conceivable,
it is not entirely clear how both antibodies would have a
potentiating effect on ADCC, particularly in cell lines that do
not overexpress HER2/neu. We are tempted to speculate that
because pertuzumab and trastuzumab are known to recognise two
different HER2/neu epitopes, the combined use of both antibodies
may have caused a net increase in antibody binding to the surface
of HER2/neu-positive tumour cells and, consequently, an in-
creased tumour susceptibility to trastuzumab and pertuzumab-
mediated ADCC. Flow cytometry data showing a significant
increase in HER2/neu receptor expression on the surface of
primary USPC cell lines using the combination of pertuzumab and
trastuzumab when compared with both mAbs used alone are
consistent with this hypothesis.
Our results also show that pertuzumab instigates CDC against
USPC cells in culture. When human plasma (up to 50%) was added
to the cytotoxicity assay, it produced an increase in the level of
tumour cell lysis, most likely an effect of the complement proteins
present in the plasma. Human plasma also contains endogenous
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tively inhibit or reduce the binding of pertuzumab with the low
affinity Fc receptors on PBLs.
Previous reports investigating the anti-tumour effects of mAbs
have shown that trastuzumab retains about 40% of its anti-tumour
activity in FcgRIII /  mice compared with wild-type mice, indi-
cating that some biological effects of mAbs can be indepen-
dent of Fc receptor binding (Clynes et al, 2000). Consistent with
these data, in this study, we tested the potential cytostatic effect
of pertuzumab to that of trastuzumab in multiple USPC primary cell
lines expressing different levels of HER2/neu expression. Although
both mAbs induced a significant inhibition in the proliferation
of the primary USPC cell lines tested, regardless of their high or
low HER-2/neu expression, pertuzumab was consistently found to
be more effective than trastuzumab in inhibiting tumour prolifera-
tion. Finally, the combination of pertuzumab and trastuzumab was
more cytostatic than trastuzumab mAb used alone. Taken together,
these results further support a potential synergistic effect of the
mAb combination on signal transduction inhibition in USPC.
In the clinic, trastuzumab (Herceptin) has been FDA approved
as first-line therapy for metastatic breast cancer that overexpress
HER2/neu (Slamon et al, 2001; Vogel et al, 2002). Given the high
expression of HER2/neu in USPC, Villella et al (2006) and Santin
et al (2008) have recently reported on the clinical use of
trastuzumab, either as a single agent or in combination with
chemotherapy, in patients with recurrent and/or chemotherapy-
resistant USPC, with encouraging results. Indeed, in these clinical
studies, a complete and a partial response were reported by Villella
et al (2006) in two heavily pretreated USPC patients with the use of
trastuzumab as a single agent, whereas Santin et al (2008)
demonstrated a dramatic clinical improvement in two further
USPC patients after the initiation of therapy with trastuzumab,
with clinical responses confirmed by serial computerised tomo-
graphy scan images and CA125 evaluations. Because pertuzumab
was found to have similar pharmacokinetic and safety profiles to
trastuzumab in animal models, it subsequently entered clinical
development (Adams et al, 2006). In phase-I studies, pertuzumab
was well tolerated, with the most common adverse events being
fatigue, nausea, and vomiting (Agus et al, 2005). The maximum
tolerated dose was not reached with dose escalation to 15mgkg
 1,
and pharmacokinetic studies indicated a terminal elimination half-
life of 2–4 weeks (Adams et al, 2006). Pertuzumab was studied in a
phase-II multicentre trial in advanced, refractory ovarian cancer.
In a total of 123 patients, there were five patients with a partial
response, eight with stable disease, and ten with a decreased
CA-125. Overall progression-free survival (PFS) was 6.6 weeks.
erbB2 was overexpressed in 28% of patients. In this cohort, PFS
was 20.9 weeks (Gordon et al, 2006).
In conclusion, we have shown for the first time that pertuzumab
alone or in combination with trastuzumab may induce a high level
of ADCC and is endowed with significant cytostatic effect against
biologically aggressive USPC cell lines expressing varying levels
of HER2/neu. On the basis of these results, we suggest including
pertuzumab in phase-II protocols for patients with advanced,
recurrent, and/or refractory USPC that overexpresses HER2/neu.
The efficacy and safety of combining pertuzumab and trastuzumab
in USPC tumours that do not overexpress erbB2 also warrant
further investigation.
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